BioPharma Resources

Drug Trial Radar · NCT07629440

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,230

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Jun 5, 2029

Study completion Jun 5, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 211 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use when given with other childhood vaccines. To measure how the new pneumococcal vaccine compares to the current one, blood samples will be used to measure the body's ability to create proteins to fight those germs. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are three groups in this study. All participants will be assigned to one of the three groups. This study is seeking participants who are: * infants who are 2 months of age in Group 1; * infants who are 2 to 6 months of age in Groups 2 and 3; and * said to be healthy by the study doctor About 3000 infants will be assigned to Group 1. The infants in this group will have a 1 in 2 chance (50%) of receiving either PG4 (new vaccine) or 20vPnC (currently in use) into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. About 140 infants from outside the United States will be assigned to Group 2. The infants in this group will have a 1 in 2 chance (50%) of receiving either PG4 or 20vPnC into the left thigh muscle at 2 to 6, 3 to 8, 4 to 10, and 12 to 15 months of age. About 90 infants from outside the United States will be assigned to Group 3. The infants in Group 3 will have a 1 in 3 chance (33%) of receiving either PG4 into the left thigh muscle, PG4 under the skin of the left thigh, or 20vPnC into the left thigh muscle at 2 to 6, 3 to 8, 4 to 10, and 12 to 15 months of age. Infants in Group 1 will take part in this study for about 16 to 19 months (about 1 and a half years). Infants in Groups 2 and 3 will take part in this study for 12 to 21 months (about 1 to 1 and a half years). During this time, infants will have 6 study clinic visits and 1 phone call. At these study clinic visits, parent(s)/legal guardian(s) will be asked if the infant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine. Infants will have 3 blood samples collected.

Conditions

  • Pneumococcal Disease

Interventions

  • PG4Biological

    Multivalent Pneumococcal Vaccine

  • 20-valent pneumococcal conjugate vaccine (20vPnC)Biological

    20-valent pneumococcal conjugate vaccine (20vPnC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactions within 7 days after each doseTime frame: Day 7
  2. Percentage of participants reporting systemic events within 7 days after each doseTime frame: Day 7
  3. Percentage of participants reporting adverse events (AEs) from Dose 1 to 1 month after Dose 3Time frame: Dose 1 to 1 month after Dose 3
  4. Percentage of participants reporting AEs from Dose 4 to 1 month after Dose 4Time frame: Dose 4 to 1 month after Dose 4
  5. Percentage of participants reporting serious adverse events (SAEs)Time frame: Dose 1 to 6 months after Dose 4
  6. Differences in percentages of participants with predefined pneumococcal specific immunoglobulin G (IgG) concentrations 1 month after Dose 3Time frame: 1 month after Dose 3
  7. Pneumococcal IgG geometric mean concentrations (GMCs) 1 month after Dose 4Time frame: 1 month after Dose 4

Locations

134 sites in 3 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics, LLC Birmingham Pediatric Associates

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama · Recruiting

  • Northwest Arkansas Pediatric Clinic

    Fayetteville, Arkansas · Recruiting

  • The Children's Clinic of Jonesboro, P.A.

    Jonesboro, Arkansas · Recruiting

  • Helios Clinical Research

    Sherwood, Arkansas · Recruiting

  • Advanced Research Center, Inc.

    Anaheim, California · Recruiting

  • San Gabriel Woman's Health

    Arcadia, California · Recruiting

  • Coast Clinical Research, LLC

    Bellflower, California · Recruiting

  • Family Medical Clinic

    El Monte, California · Recruiting

  • Clinical Research of Central California

    Fresno, California · Recruiting

  • Investigational Drug Services, Bowyer Pharmacy

    Los Angeles, California · Not yet recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Not yet recruiting

  • UCLA (outpatient clinic)

    Los Angeles, California · Not yet recruiting

  • UCLA

    Los Angeles, California · Not yet recruiting

  • SeraCollection Research Services, LLC

    Montebello, California · Recruiting

  • Bailony Pediatrics

    National City, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Not yet recruiting

  • Childrens Hospital of Colorado

    Aurora, Colorado · Recruiting

  • Direct Helpers Research Center

    Hialeah, Florida · Recruiting

  • C & R Research Services USA

    Homestead, Florida · Recruiting

  • Florida Pharmaceutical Research and Associates, Inc.

    Miami, Florida · Recruiting

  • International Research II, LLC.

    Miami, Florida · Not yet recruiting

  • Bioresearch Partner

    Miami, Florida · Recruiting

  • Gold Coast Health Research Center, LLC

    Miami, Florida · Recruiting

  • Dade Research Center

    Miami, Florida · Recruiting

  • Vasconcello-Cohen MD Research, LLC.

    Miami, Florida · Recruiting

  • Barroso Medical Services LLC

    Miami Lakes, Florida · Recruiting

  • Riveldi and Associates

    Miami Lakes, Florida · Recruiting

  • Eminent Clinical Research and Associates

    North Lauderdale, Florida · Recruiting

  • Cordova Research Institute LLC

    Sweetwater, Florida · Recruiting

  • South Tampa Center for Advanced Healthcare- USF Health

    Tampa, Florida · Recruiting

  • USF Health

    Tampa, Florida · Recruiting

  • USF Health Department of Pediatrics The Chalsty Clinics at the Curran Children's Health Center (CMS)

    Tampa, Florida · Recruiting

  • Children's Health Center

    Tampa, Florida · Recruiting

  • ObjectiveHealth Clinical Research LLC - Chamblee

    Chamblee, Georgia · Recruiting

  • Altruistic Clinical Research Global

    Norcross, Georgia · Recruiting

  • Medical Research Partners

    Ammon, Idaho · Recruiting

  • Bingham Memorial Hospital

    Blackfoot, Idaho · Recruiting

  • ASR, LLC

    Boise, Idaho · Recruiting

  • Leavitt Clinical Research

    Idaho Falls, Idaho · Recruiting

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.